Zhu Yong-Zhang, Li Qing-Tian, Wang Li, Zhong Yi, Ding Guo-Hui, Li Guang, Jia Pei-Ling, Shi Tie-Liu, Guo Xiao-Kui
Department of Medical Microbiology and Parasitology, Institutes of Medical Sciences, Shanghai Jiao Tong University School of Medicine, 200025 Shanghai, People's Republic of China.
OMICS. 2008 Sep;12(3):161-9. doi: 10.1089/omi.2008.0029.
Whooping cough (pertussis) caused by B. pertussis (B.p) is still serious public health threat. B. parapertussis (B.pp), closely related to B.p, also causes whooping cough. The incidence of B.pp infections has been increasing over the last decades, partly because pertussis vaccines have low efficiency against B.pp infections. Moreover, because the majority of pertussis patients are infants, common antimicrobial agents producing serious adverse reactions in infants are not fully satisfactory. Therefore, we try to identify potential vaccine candidates and alternative drug targets against both B.p and B.pp. This preliminary work integrates several different kinds of data from in silico analysis, comparative genomic hybridization, global transcriptional profiling, and protein-protein interaction (PPI) network to screen potential vaccine candidates and drug targets against the two species. Finally, 191 potential crossprotective vaccine candidates are identified. They have high transcriptional levels in both species, or are associated with virulence and pathogenesis. Moreover, these proteins are not only potentially surface-exposed in the bacteria, but also well conserved among the 165 B.p and B.pp strains. Among them, 22 candidates with high essentiality in the two PPI networks of B.p and B.pp are regarded as suitable drug targets against the two species. We just selected Bordetella as an example to develop a rapid and reliable approach for screening alternative drug targets that associated with novel protein pathways, complexes, and cellular functions against these antibiotic-resistant pathogens. Further researches focusing on the 191 vaccine candidates could accelerate the development of more effective vaccines and drug therapy against B.p and B.pp infection.
由百日咳博德特氏菌(B. pertussis,简称B.p)引起的百日咳仍是严重的公共卫生威胁。与B.p密切相关的副百日咳博德特氏菌(B. parapertussis,简称B.pp)也会引发百日咳。在过去几十年中,B.pp感染的发病率一直在上升,部分原因是百日咳疫苗对B.pp感染的效率较低。此外,由于大多数百日咳患者是婴儿,在婴儿中会产生严重不良反应的常见抗菌药物并不完全令人满意。因此,我们试图确定针对B.p和B.pp的潜在疫苗候选物和替代药物靶点。这项初步工作整合了来自计算机分析、比较基因组杂交、全局转录谱分析和蛋白质-蛋白质相互作用(PPI)网络的几种不同类型的数据,以筛选针对这两种细菌的潜在疫苗候选物和药物靶点。最终,确定了191种潜在的交叉保护疫苗候选物。它们在这两种细菌中都具有高转录水平,或者与毒力和发病机制相关。此外,这些蛋白质不仅可能在细菌表面暴露,而且在165株B.p和B.pp菌株中高度保守。其中,在B.p和B.pp的两个PPI网络中具有高必需性的22种候选物被视为针对这两种细菌的合适药物靶点。我们仅以博德特氏菌为例,开发了一种快速可靠的方法,用于筛选与针对这些耐药病原体的新蛋白质途径、复合物和细胞功能相关的替代药物靶点。针对这191种疫苗候选物的进一步研究可以加速开发针对B.p和B.pp感染的更有效疫苗和药物疗法。